pharmaceuticals

SB 147, as heard by the Senate Health Committee, would lift an expiration date on a law that restricts pharmacists’ ability to prescribe biosimilars, or generic alternatives to complex biological drugs. The bill also expands that law to include insulin. California Gov. Jerry Brown vetoed a very similar law, citing increased costs to state-purchased health plans.

Have You Ever Wondered? - How Clinical Trials Are Developed - What Steps Are In Drug Discovery Processes - How Patient Voice & Participation Can Improve The Innovation Process

BERLIN – June 28, 2012 -- Now that the Supreme Court has upheld President Obama’s healthcare plan, pharmaceutical companies, patients and healthcare experts in Europe are waiting to see how a new cost reducing drug price mechanism affects them.Requiring citizens to have healthcare has long been a staple of European health insurance programs. But now governments and insurers are trying to stem the cost of exorbitantly expensive new drugs.